Physician profile
Brooke Lyons
NPI 1225430077
$1,920.38
in general payments reported to CMS, 2019-2025
19 companies · $745 in 2025
The $745 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.77 · 2022: $85.21 · 2023: $400 · 2024: $622 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.41 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.71 | 2021-2025 | |
| Harmony Biosciences LLC | $191.87 | 2023-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $183.95 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $171.14 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $133.09 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $119.85 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $118.68 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $111.74 | 2023-2025 | Sunosi, Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.96 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $89.73 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Corium, LLC | $89.32 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $77.62 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $62.83 | 2024-2025 | Cobenfy |
| Livanova USA, INC. | $55.05 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Ironshore Pharmaceuticals INC. | $34.82 | 2023-2024 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $34.39 | 2023-2025 | Nuplazid |
| Indivior INC. | $19.26 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.11 | 2025 | Jornay Pm |
| Eisai INC. | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.